[ad_1]
Restoration Robotics (NASDAQ:HAIR) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.
Earnings & Valuation
This table compares Restoration Robotics and Haemonetics’ top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Restoration Robotics | $21.30 million | 1.76 | -$17.84 million | ($2.50) | -0.37 |
Haemonetics | $903.92 million | 4.97 | $45.57 million | $1.87 | 47.13 |
Haemonetics has higher revenue and earnings than Restoration Robotics. Restoration Robotics is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
31.2% of Restoration Robotics shares are held by institutional investors. Comparatively, 98.5% of Haemonetics shares are held by institutional investors. 37.8% of Restoration Robotics shares are held by insiders. Comparatively, 1.0% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Restoration Robotics has a beta of 4.98, suggesting that its stock price is 398% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Restoration Robotics and Haemonetics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Restoration Robotics | 0 | 0 | 3 | 0 | 3.00 |
Haemonetics | 0 | 0 | 3 | 0 | 3.00 |
Restoration Robotics presently has a consensus price target of $8.50, indicating a potential upside of 823.91%. Haemonetics has a consensus price target of $119.00, indicating a potential upside of 35.03%. Given Restoration Robotics’ higher possible upside, analysts plainly believe Restoration Robotics is more favorable than Haemonetics.
Profitability
This table compares Restoration Robotics and Haemonetics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Restoration Robotics | -103.09% | -324.32% | -75.33% |
Haemonetics | 4.84% | 17.05% | 9.50% |
Summary
Haemonetics beats Restoration Robotics on 9 of the 12 factors compared between the two stocks.
About Restoration Robotics
Restoration Robotics, Inc., a medical device company, develops and commercializes image-guided robotic systems in the United States and internationally. The company offers ARTAS System, a physician-assisted robotic system that identifies and dissects hair follicular units directly from the scalp and creates recipient implant sites. Its system includes the ARTAS Hair Studio application, an interactive three-dimensional patient consultation tool that enables a physician to create a simulated hair transplant model for use in patient consultations. The company was founded in 2002 and is headquartered in San Jose, California.
About Haemonetics
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Receive News & Ratings for Restoration Robotics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Restoration Robotics and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link
Leave A Comment
You must be logged in to post a comment.